Hai Wang
Impact in
- Pharmaceutical Science top 5%
- Advancements in Transdermal Drug Delivery
- Immunology top 10%
- Immunotherapy and Immune Responses
Papers in
-
- Nicotinic Acetylcholine Receptors Study 8
- Receptor Mechanisms and Signaling 7
- Protein Degradation and Inhibitors 7
- Ubiquitin and proteasome pathways 6
- Oncology 15
- Peptidase Inhibition and Analysis 6
- Co-authors
- Guangjun Nie (16 shared papers)Xiu‐Lan Sun (2 shared papers)Jie Zhang (16 shared papers)Wenping Huang (17 shared papers)Yue Yin (5 shared papers)Haixia Ma (6 shared papers)Fuhao Jia (8 shared papers)Di Yu (5 shared papers)
- Journals
- Nano Letters (4 papers)Nano Today (4 papers)ACS Nano (3 papers)Advanced Materials (3 papers)Nature Nanotechnology (2 papers)
- Partner nations
- ChinaUnited StatesSweden
In The Last Decade
Hai Wang
86 papers receiving 1.5k citations
Peers
Comparison fields: 5 of 121
- Pharmaceutical Science 106
- Immunology 276
- Molecular Biology 728
- Biomaterials 140
- Biomedical Engineering 326
Countries citing papers authored by Hai Wang
This map shows the geographic impact of Hai Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hai Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hai Wang more than expected).
Fields of papers citing papers by Hai Wang
This network shows the impact of papers produced by Hai Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hai Wang. The network helps show where Hai Wang may publish in the future.
Co-authors
The 25 scholars most cited alongside Hai Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 89 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 169 | |
| 2 | 2004 | 125 | |
| 3 | 2021 | 102 | |
| 4 | 2023 | 94 | |
| 5 | 2022 | 77 | |
| 6 | 2019 | 70 | |
| 7 | 2018 | 53 | |
| 8 | 2022 | 49 | |
| 9 | 2024 | 48 | |
| 10 | 2023 | 37 | |
| 11 | 2024 | 36 | |
| 12 | 2022 | 31 | |
| 13 | 2020 | 29 | |
| 14 | 2016 | 28 | |
| 15 | Vessel dilator and kaliuretic peptide inhibit ERK 1/2 activation in human prostate cancer cells. | 2006 | 27 |
| 16 | 2017 | 26 | |
| 17 | Novel autoantigens in type 1 diabetes. | 2013 | 26 |
| 18 | 2022 | 25 | |
| 19 | 2023 | 24 | |
| 20 | 2013 | 23 |
About Hai Wang
Hai Wang is a scholar working on Molecular Biology, Oncology, Immunology, Cancer Research and Biomedical Engineering, having authored 89 papers that have together received 1.5k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (8 papers), Nicotinic Acetylcholine Receptors Study (8 papers), Receptor Mechanisms and Signaling (7 papers), Protein Degradation and Inhibitors (7 papers), Ubiquitin and proteasome pathways (6 papers), Peptidase Inhibition and Analysis (6 papers), Nanoplatforms for cancer theranostics (6 papers) and Cancer, Hypoxia, and Metabolism (5 papers). The work is most often cited by research in Pharmaceutical Science (106 citations), Immunology (276 citations), Molecular Biology (728 citations), Biomaterials (140 citations) and Biomedical Engineering (326 citations). Hai Wang has collaborated with scholars based in China, United States and Sweden. Frequent co-authors include Guangjun Nie, Xiu‐Lan Sun, Jie Zhang, Wenping Huang, Yue Yin, Haixia Ma, Fuhao Jia, Di Yu, Shengji Yu and Xiaoyang Li. Their work appears in journals such as Nano Letters, Nano Today, ACS Nano, Advanced Materials and Nature Nanotechnology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.